Last week saw a number of broker notes hitting the wires once again. Three buy ratings that investors might want to be aware of are summarised below.
Here's why brokers think investors ought to buy them next week:
Image source: Getty Images
CSL Limited (ASX: CSL)
According to a note out of Citi, its analysts have retained their buy rating but trimmed their price target slightly on this biotherapeutics company's shares to $335.00. This follows the release of the company's half year results, which has eased concerns about plasma collections headwinds. Citi also notes that management has effectively upgraded its FY 2022 guidance by 5%. The CSL share price ended the week at $265.57.
Challenger Ltd (ASX: CGF)
A note out of Morgan reveals that its analysts have retained their add rating and lifted their price target on this annuities company's shares to $7.74. This follows the release of a half year result that came in ahead of expectations. Overall, the broker was impressed with Challenger's performance and highlights its good asset growth in both Life and Funds Management, and a broadly stable Life COE margin at an underlying level. In light of this positive form, it believes the company's shares are trading on undemanding multiples. The Challenger share price was fetching $6.73 at the end of the week.
Goodman Group (ASX: GMG)
Another note out of Citi reveals that its analysts have retained their buy rating and lifted their price target on this integrated property company's shares to $29.50. Citi notes that Goodman's half year results came in ahead of its expectations. And while management has once again upgraded its guidance, the broker still believes Goodman is being conservative and expects the company to outperform it. The Goodman share price closed the week at $23.06.
